verapamil has been researched along with bortezomib in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Frey, B; Gaipl, US; Lang, VR; Meister, S; Schett, G; Schlötzer-Schrehardt, U; Voll, RE | 1 |
| Ao, L; Jang, ER; Kim, D; Kim, K; Kim, KB; Lee, DM; Lee, W; Wu, Y | 1 |
| Chen, Z; Fayad, L; Kwak, LW; McCarty, N; Romaguera, J; Wang, M | 1 |
1 review(s) available for verapamil and bortezomib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
7 other study(ies) available for verapamil and bortezomib
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calcium Channel Blockers; Cell Death; Cell Survival; Drug Evaluation, Preclinical; Drug Synergism; Endoplasmic Reticulum; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Stress, Physiological; Treatment Outcome; Tumor Cells, Cultured; Unfolded Protein Response; Verapamil | 2010 |
Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Humans; Oligopeptides; Peptides; Proteasome Inhibitors; Pyrazines; Verapamil | 2012 |
Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Male; Pyrazines; Reactive Oxygen Species; Tumor Cells, Cultured; Vasodilator Agents; Verapamil | 2012 |